Tirzepatide vs Retatrutide
Dual vs Triple Agonist Compared
Tirzepatide (GLP-1/GIP) vs retatrutide (nicknamed "Reta," GLP-1/GIP/glucagon). Compare Phase 3 weight loss data, MASH results, thermogenic effects, and when to switch.
Today's Champion vs. The Next-Generation Triple Agonist
Tirzepatide (GLP-1 + GIP) is FDA approved and produces ~20% weight loss in pivotal programs. Retatrutide adds glucagon receptor agonism and has now reported a first positive Phase 3 readout (TRIUMPH-4, December 2025).
Here is the full comparison of what you can take today versus what is still investigational. Tirzepatide: GLP-1 + GIP Dual Agonist Tirzepatide was the first dual incretin agonist — hitting both GLP-1 and GIP receptors simultaneously.
GLP-1 suppresses appetite and slows gastric emptying; GIP acts on fat cells and the brain to further reduce food intake and promote energy expenditure. The combination produces more weight loss than any single-agonist GLP-1 drug and earned FDA approval for both type 2 diabetes (Mounjaro) and obesity (Zepbound), plus obstructive sleep apnea.
Retatrutide: GLP-1 + GIP + Glucagon Triple Agonist Retatrutide adds glucagon receptor agonism to the GLP-1/GIP base. Glucagon agonism increases thermogenesis (raises resting metabolic rate), drives hepatic fat oxidation (directly reducing liver fat), and may sustain weight loss by preventing the metabolic adaptation that slows weight loss on other GLP-1 drugs.
This is why retatrutide Phase 2 data showed the largest weight loss ever recorded in an obesity trial.
Who Should Choose Which?
Use Tirzepatide Now If… ✓ You have obesity, T2D, or obstructive sleep apnea and need FDA-approved treatment available today. ✓ You want proven Phase 3 data, not Phase 2 results — tirzepatide has SURMOUNT-1 through -4, with 20%+ weight loss confirmed across large trials.
✓ You have liver disease (MASH/MASLD) — tirzepatide already has strong hepatic fat reduction data (SURMOUNT-NASH trial). ✓ You can access it through insurance, a manufacturer coupon program, or compounding pharmacy at lower cost.
Watch Retatrutide If… ✓ You have severe MASH or advanced metabolic fatty liver disease and the hepatic glucagon mechanism is specifically important to you. ✓ You have plateaued on tirzepatide at dose and want to understand what options may exist when retatrutide becomes available.
✓ You are interested in a thermogenic mechanism — the glucagon-driven increase in resting metabolic rate is a genuinely novel benefit not available in current GLP-1 drugs. ✓ You are in or eligible for the TRIUMPH Phase 3 trials and want access to cutting-edge data.
Making an Informed Choice Between Tirzepatide and Retatrutide
Choosing between Tirzepatide and Retatrutide depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Tirzepatide and Retatrutide is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Tirzepatide vs Retatrutide: Frequently Asked Questions
Tirzepatide (GLP-1/GIP) vs retatrutide (GLP-1/GIP/glucagon). Compare Phase 3 weight loss data, MASH results, thermogenic effects, and when to switch.
Yes. Shotlee supports tracking doses, side effects, and health metrics. It is free.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Both Protocols in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
📚References & sources
Latest on Tirzepatide
Anandita Sundar's 7-Year Weight Loss Journey and Body Shaming
Anandita Sundar opens up about her seven-year weight loss journey, highlighting the profound impact of body shaming on mental health and her commitment to prioritizing well-being over societal expectations.
7 min read
Plus-Size Swimsuit Model on Inclusivity Amidst GLP-1 Medications
Plus-size model Hunter McGrady shares her concerns about a perceived decline in fashion inclusivity, particularly in the context of the growing popularity of GLP-1 weight loss medications.
7 min read
Black-Market Peptide Surge Strains Needle and Syringe Programs
The rise of unregulated peptides for performance and image enhancement is placing significant pressure on vital harm reduction services, originally established to combat HIV. These programs are now facing increased demand and potential shortages of essential supplies.
7 min read